Next 10 |
SPARKS, NV / ACCESSWIRE / March 27, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased to announce that its subsidiary Exousia AI is funding a preclinical study on Glioblastoma (GBM), an incurable brain cancer. The study is being done in the lab of Dr. K...
SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence cancer screening market. The company, with its wholly owned subsidiary M-RNA for Life, has enlisted the...
SPARKS, Nev., March 06, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc. (OTC: LUDG): A US-based biotechnology company is pleased to announce the successful filing of its provisional patent, title “mRNAs differentially expressed in colorectal cancer, breast cancer, and bladder cancer....
SPARKS, NV / ACCESSWIRE / January 31, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased to announce that the company has received Continuing Review Approval on its planned clinical study from Advarra IRB, Columbia, MD. Ludwig clinical study LL301 is tit...
SPARKS, NV / ACCESSWIRE / January 9, 2024 / Ludwig Enterprises, Inc, (OTC:LUDG): A US based biotechnology company with a mission to develop cargo delivery platforms containing genetic mRNA and DNA, and nutritional compounds is pleased to announce that its subsidiary Exousia AI has signed a contr...
SPARKS, NV / ACCESSWIRE / November 16, 2023 / Ludwig Enterprises, Inc., the Genomics Language Company™, focused on the development of personalized diagnostics and therapeutics targeting illnesses such as cancer, diabetes, COPD and heart disease, today announced the appointment of Scott Si...
SPARKS, NV / ACCESSWIRE / November 14, 2023 / Ludwig Enterprises, Inc., (OTC PINK:LUDG) , a developer and provider of innovative medical technologies, announced today that the U.S. Securities and Exchange Commission (SEC) has declared the Company's Registration Statement on Form S-1 (File No. 3...
2023-09-19 07:09:36 ET Ludwig ( OTCPK:LUDG ) has announced that Marvin S. Hausman MD has joined as Chief Executive Officer. Marvin S. Hausman, M.D. has served as a key consultant to our company since July 2022. Dr. Hausman is an Immunologist and Board-Certified Urological Surgeon ...
SPARKS, NV / ACCESSWIRE / September 19, 2023 / Ludwig (OTC:LUDG) , a provider of innovative medical technologies, announced today Marvin S. Hausman MD has joined Ludwig Enterprises, Inc as Chief Executive Officer. "I am excited about the research and commercial direction of Ludwig and its new ...
Ludwig Enterprises Files Cancer Genomic Patent Machine Learning AI Uncovers Differentially Expressed Genes SPARKS, NV / ACCESSWIRE / May 9, 2023 / Ludwig Enterprises, Inc, (OTC PINK:LUDG) (Ludwig - The Genomics Language Company™) is pleased to announce that recently analyzed geno...
News, Short Squeeze, Breakout and More Instantly...
Ludwig Enterprises Company Name:
LUDG Stock Symbol:
OTCMKTS Market:
SPARKS, NV / ACCESSWIRE / March 27, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased to announce that its subsidiary Exousia AI is funding a preclinical study on Glioblastoma (GBM), an incurable brain cancer. The study is being done in the lab of Dr. K...
SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence cancer screening market. The company, with its wholly owned subsidiary M-RNA for Life, has enlisted the...
SPARKS, Nev., March 06, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc. (OTC: LUDG): A US-based biotechnology company is pleased to announce the successful filing of its provisional patent, title “mRNAs differentially expressed in colorectal cancer, breast cancer, and bladder cancer....